Regarding the management and pathophysiology of hyponatremia, all of the following statements are correct EXCEPT:

Explanation

## Hyponatremia Management: Principles and Pitfalls This question tests critical knowledge of hyponatremia correction rates, SIADH management, and the pharmacology of desmopressin (DDAVP). ### Key Principle: Identifying the INCORRECT Statement In an "all EXCEPT" question, we must identify the one statement that is **factually wrong**. --- ### Analysis of Each Statement #### Statement A: Rapid Correction of Chronic Hyponatremia → ODS Risk ✓ CORRECT - Chronic hyponatremia (>48 hrs) allows the brain to adapt by reducing intracellular osmolytes (taurine, betaine, sorbitol, myoinositol) - Rapid correction (>8–10 mEq/L per 24 hrs) causes water to leave brain cells faster than osmolytes can be replenished - Result: brain cell shrinkage, demyelination → **Osmotic Demyelination Syndrome (ODS)**, formerly called central pontine myelinolysis - This statement is **entirely correct** *(Harrison's Principles of Internal Medicine, 21st ed.)* #### Statement B: DDAVP Use and Contraindications ✗ **INCORRECT — This is the EXCEPTION** **High-Yield:** The statement claims DDAVP is "contraindicated in nephrogenic DI" — this is **factually inaccurate**: | Condition | DDAVP Use | |-----------|-----------| | **Central DI** | ✓ Treatment of choice (replaces deficient ADH) | | **Nephrogenic DI** | ⚠️ Generally **ineffective** (kidneys don't respond to ADH), but **NOT contraindicated** — high-dose DDAVP may have partial benefit in mild/partial nephrogenic DI (e.g., lithium-induced); thiazides + NSAIDs are preferred | | **SIADH** | ✗ **Contraindicated** (ADH already elevated; DDAVP would worsen hyponatremia by further promoting free water retention) | The blanket statement that DDAVP is "contraindicated in nephrogenic DI" is **factually incorrect**. It is *ineffective* (not contraindicated) in nephrogenic DI. The true contraindication is in **SIADH**, where exogenous ADH agonism worsens the underlying pathology. **Clinical Pearl:** The pharmacological distinction between "ineffective" and "contraindicated" is critical. DDAVP is contraindicated in SIADH (worsens hyponatremia), but merely ineffective in nephrogenic DI — not contraindicated. *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed.; Harrison's, 21st ed.)* #### Statement C: Rapid Hypertonic Saline in Symptomatic Hyponatremia ✓ CORRECT - Symptomatic hyponatremia (seizures, coma, impending herniation) is a **medical emergency** requiring immediate treatment with 3% hypertonic saline - Current guidelines (European Hyponatremia Guidelines 2014; Sterns et al.) recommend: bolus 100–150 mL of 3% NaCl IV over 10–20 minutes, repeated up to 3 times if needed - Target: raise serum sodium by 4–6 mEq/L acutely to stop seizures/prevent herniation - This acute bolus approach applies **regardless of chronicity** when there is life-threatening neurological compromise - After acute stabilization, correction is slowed to ≤8–10 mEq/L per 24 hrs in chronic cases - This statement is **correct** #### Statement D: Fluid Restriction in Euvolemic SIADH ✓ CORRECT - SIADH is euvolemic hyponatremia with inappropriately elevated ADH - Fluid restriction (typically 800–1000 mL/day) reduces free water intake, allowing gradual sodium correction - **First-line treatment** for chronic, asymptomatic SIADH - This statement is **correct** --- ### Summary Table | Statement | Correct? | Why | |-----------|----------|-----| | A. ODS risk with rapid chronic correction | ✓ Yes | Pathophysiology is accurate | | **B. DDAVP contraindicated in nephrogenic DI** | ✗ **No** | DDAVP is *ineffective* (not contraindicated) in nephrogenic DI; it is contraindicated in SIADH | | C. Rapid 3% saline in symptomatic hyponatremia | ✓ Yes | Acute bolus indicated for seizures/herniation regardless of chronicity | | D. Fluid restriction in SIADH | ✓ Yes | First-line, evidence-based | **Key Point:** DDAVP is contraindicated in SIADH (worsens hyponatremia by further stimulating V2 receptors), but is merely *ineffective* — not contraindicated — in nephrogenic DI, where the renal tubules are unresponsive to ADH signaling regardless of dose.